Stanfield, Brad http://orcid.org/0000-0003-1004-2039
Kaeberlein, Matt
Leroux, Brian
Jones, Julie
Lucas, Ruth
Arroll, Bruce
Article History
Received: 17 July 2024
Accepted: 20 September 2024
First Online: 1 October 2024
Declarations
:
: The study titled “A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate safety and efficacy of intermittent rapamycin on muscle strength and endurance in older adults following a 13-week exercise program” has been approved by the Northern B Health and Disability Ethics Committee (HDEC) in New Zealand. The ethics reference number for this approval is 2024 FULL 20084. This approval includes the completion of non-standard conditions before the commencement of the study, ensuring compliance with HDEC requirements.This study will be conducted in accordance with the protocol and with the following:• Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organisations of Medical Sciences (CIOMS) international ethical guidelines.• Applicable ICH Good Clinical Practice Guidelines (GCP)• Applicable laws and regulations.New Zealand National Ethics Advisory Committee (NEAC) Guidelines.
: Not applicable. This manuscript does not contain any details, images, or videos relating to an individual person. If requested, the authors are willing to provide a model consent form and other related documentation given to participants and authorized surrogates.
: There are no competing interests to declare.